Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
China Chemical & Pharmaceutical Co. Ltd. currently manages 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner and 1 distinct art unit. The concentration of the company's current prosecution into a single matter suggests a highly focused approach to its intellectual property development. For practitioners, this means that the immediate success of the portfolio depends entirely on the outcome of this specific negotiation within the Biotechnology & Pharmaceuticals sector.
The busiest examiner for this portfolio is GALSTER, SAMUEL LEONARD, who is responsible for 1 busiest examiner pending action. Because this individual is the only examiner currently engaged with the company's pending applications, the relationship with this specific official is paramount. There are no other 1 distinct examiners to provide a baseline for comparison or to offer alternative paths for patent allowance within the current workload. The prosecution strategy must therefore be tailored specifically to the preferences of this one examiner.
The involvement of only 1 distinct art unit further simplifies the procedural landscape, as there is no need to navigate the varying standards of different examination groups. However, this lack of diversity also means that the company has no other active applications to serve as a hedge against a potential rejection. Every resource must be directed toward resolving the 1 busiest examiner pending action successfully to maintain momentum in the company's patenting efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 52.1% | +42.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651022 | PHARMACEUTICAL SOLUTION COMPOSITION AND ORAL MIST INHALER COMPRISING THE SAME | GALSTER, SAMUEL LEONARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18651022 | PHARMACEUTICAL SOLUTION COMPOSITION AND ORAL MIST INHALER COMPRISING THE SAME | GALSTER, SAMUEL LEONARD | — |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18651022 | PHARMACEUTICAL SOLUTION COMPOSITION AND ORAL MIST INHALER COMPRISING THE SAME | GALSTER, SAMUEL LEONARD | 1693 | §102§103 | Non-Final OA | — | Pending | Apr 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialChina Chemical & Pharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samuel Leonard Galster has the most, with 1 of China Chemical & Pharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
